Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Immunomedics
Thumbnail
April 13, 2021

Quiet times return for biopharma takeouts

The first quarter of 2021 saw fewer deals than any in recent memory.

Thumbnail
January 06, 2021

Astrazeneca shows megamergers were still possible in 2020

One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.

Article image
Vantage logo
December 14, 2020

Astrazeneca rescues biopharma's 2020 takeover scorecard

Article image
Vantage logo
October 07, 2020

Gilead rescues biopharma’s takeout scene

A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.

Article image
Vantage logo
September 14, 2020

Gilead’s cancer ambitions stretch to $21bn

As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.

Article image
Vantage logo
September 11, 2020

Esmo 2020 preview – late-breaking immunotherapy

The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.

Article image
Vantage logo
July 27, 2020

Another Astra-Daiichi tie-up puts Trop2 in focus

The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.

Article image
Vantage logo
July 07, 2020

Immunomedics confirms its approval within three months

Article image
Vantage logo
June 24, 2020

Important catalysts approach for smaller biotechs

Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.

Article image
Vantage logo
May 01, 2020

US FDA approval tracker: April

Article image
Vantage logo
April 23, 2020

Immunomedics refuses to be caught on the hop

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.